ExpreS2ion will participate in key industry and investor events
Hørsholm, Denmark, August 15, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include a presentation of Q2 2022 results (August 18), the LSX Nordic Investor Conference (September 6-7), and PIVAC-22, a forum covering the most recent advances in cancer immunotherapy (September 26-28).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS2 technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.
Presentation of Q2 2022 results at the H.C. Andersen Capital webinar, August 18 at 14:00 CET
ExpreS2ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the Q2 2022 results and answer investors’ questions. More information and registration can be found on the H.C. Andersen Capital events website.
LSX Nordic Congress, September 6-7, Copenhagen, Denmark
An opportunity for investors and potential partners to meet ExpreS2ion CEO Bent U. Frandsen and CFO Keith Alexander in 1-on-1 meetings. More information and registration can be found on the LSX Nordic website.
Progress in Vaccination Against Cancer (PIVAC-22), September 26-28, Torino, Italy
Meet ExpreS2ion’s VP of Preclinical Development, Dr. Mette Thorn, and hear the company’s preclinical development partners from the University of Bologna present on "Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine,” in a forum covering the most recent advances in the field of cancer immunotherapy. More information and registration can be found on the PIVAC-22 website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.